Organic Process Research & Development 2009, 13, 924–927
Technical Notes
An Improved and Scaleable Preparation of 7-Amino-3-vinylcephem-4-carboxylic acid
Mingyong Chao and Aiyou Hao*
School of Chemistry and Chemical Engineering, Shandong UniVersity, Jinan 250100, P.R. China
Abstract:
and the limited availability of DCC. Although some companies
are producing 1 by the routes shown in Scheme 2, the above
shortcomings and the low overall yield make the process
uneconomical. Scheme 3 (Route B) is obviously more practical
compared with other schemes due to fewer steps, easier
availability of raw materials, and more environmental friendli-
ness. However, there are still several drawbacks regarding
Scheme 3 (Route B) in the reported methods,10,11 namely: (1)
the overall yield (41.4-58.5%) is low; (2) trifluoroacetic acid
used in the process is relatively expensive and hazardous; (3)
product purity reported by Xu, et al. is only 92.3%, which is
insufficient for cefixime or cefdinir production. Although the
purity has been improved to 98.3% by Du, et al., the improved
process requires chromatographic purification, which is ex-
tremely inconvenient for commercial production; and (4)
isolation11 or chromatographic purification12 of intermediate 3
makes the reported processes complicated.
A practical and efficient multikilogram-scale preparation of
7-amino-3-vinylcephem-4-carboxylic acid (7-AVCA), a key inter-
mediate used in the synthesis of cefixime and cefdinir, is described
utilizing p-methoxybenzyl 7-phenylacetamido-3-chloromethylceph-
em-4-carboxylate (GCLE) as a starting material. Reaction condi-
tions were optimized to simplify the process, to improve the quality
and to increase the yield. The process has been demonstrated on
a multikilogram scale in 77% overall yield with a purity of >99%.
Introduction
7-Amino-3-vinylcephem-4-carboxylic acid (7-AVCA, 1) is
a key intermediate used in the synthesis of cefixime and
cefdinir,1-4 which are orally active third-generation cepha-
losporin antibiotics with broad antibacterial spectra.5-7 Cefixime
and cefdinir can be efficiently synthesized from 1 in 80% and
70% overall yields respectively.1,3
There are several synthetic methods reported for the prepara-
tion of 7-AVCA starting from deacetyl cephalosporin C (DCC)
(Scheme 1),8 7-amino cephalosporanic acid (7-ACA) (Scheme
2),8 or GCLE, (Scheme 3)9-12 etc.
To improve the quality and the yield, as well as to reduce
the cost and simplify the process from a commercial aspect,
we developed an improved process based on Scheme 3 (Route
B). In this contribution, a simplified scaleable process with
dramatically improved yield and quality for the preparation of
1 is described that uses GCLE as a starting material.
Schemes 1 and 2 have many shortcomings such as having
a large number of steps, using expensive and hazardous raw
materials, and being not environmentally friendly. Scheme 1
is impractical on a large scale due to the above shortcomings
Results and Discussion
Starting from GCLE, one reported literature method10,11
involves introduction of C-3 vinyl group by the Wittig reaction
to give p-methoxybenzyl 7-phenylacetamido-3-chloromethyl-
cephem-4-carboxylate (2), which when deprotected with trif-
luoroacetic acid gives 7-phenylacetamido-3-chloromethylceph-
em- 4-carboxylic acid (3). 7-AVCA (1) is finally obtained by
enzymolysis in the presence of penicillin G amidase. In this
method, the overall yield and purity of 1 are only 55% and
92.3%, respectively. 3 is isolated and dried for use in the next
step. Expensive and hazardous trifluoroacetic acid is used.
Furthermore, the crude product is washed with methanol, butyl
acetate, and acetone sequentially to remove the impurities,
making solvent recovery difficult. Another improved method12
increases the yield and purity to 58.5% and 98.3% respectively,
but trifluoroacetic acid is also used in the process, and
chromatographic purification is required to improve the quality.
In the present paper, we report an improved and scaleable
process with respect to improvement of yield and product
quality, use of less expensive raw materials, and lower
consumption of solvents. In this improved process, GCLE reacts
with sodium iodide and triphenylphosphine in a mixture of
* Author for correspondence. E-mail: haoay@sdu.edu.cn. Telephone: (86-
531) 88363306.
(1) Deshpande, P. B.; Luthra, P. K. (Orchid). U.S. Patent 6,388,070 B1,
2002.
(2) Hu, A. X.; Yuan, S.; Song, Y. Q.; Tang, F.; Song, J. S. Chin. J. Pharm.
2004, 35 (1), 3–4.
(3) Rao, K. V. V. P.; Dandala, R.; Sivakumaran, M. S.; Rani, A. Synth.
Commun. 2007, 37, 2275–2283.
(4) Lee, G. S.; Chang, Y. K.; Chun, J. P.; Koh, J. H. (Hanmi). U.S. Patent
6,093,814, 2000.
(5) Brogden, R. N.; Campoli-Richards, D. M. Drugs 1989, 38, 524–550.
(6) Inamoto, Y.; Chiba, T.; Kamimura, T.; Takaya, T. J. Antibiot. 1988,
41, 828–830.
(7) Ternansky, R. J.; Christopher, L.; Jordan, F.; Bell, W.; Theresea, G.;
Kasher, S. J. Antibiot. 1993, 46, 1897–1900.
(8) Yamanaka, H.; Chiba, T.; Kawabata, K.; Takasugi, H.; Masugi, T. J.
Antibiot. 1985, 38 (12), 1738–1751.
(9) Takaya, T.; Takasugi, H.; Masugi, T.; Yamanaka, H.; Kawabata, K.
(Fujisawa) U.S. Patent 4,960,889, 1990.
(10) Hu, S. C.; Zhou, H. S.; Bi, X. L. J. Chin. Pharm. UniV 1993, 24 (4),
246–247.
(11) Xu, S. W.; Chen, S. H.; Huang, M. K. Chin. J. Pharm. 2000, 31 (8),
367–368.
(12) Du, B. S.; Sheng, C. G.; Sun, T. M. Chin. J. Med. Chem. 2006, 16
(2), 85–87.
924
•
Vol. 13, No. 5, 2009 / Organic Process Research & Development
10.1021/op900053j CCC: $40.75 2009 American Chemical Society
Published on Web 07/02/2009